Metabolic Telehealth Startup Calibrate Raises $100M

Image: Calibrate

Digital metabolic health company Calibrate landed $100M in Series B funding co-led by Founders Fund and Tiger Global.

Optum Ventures also participated in the round alongside existing investors Forerunner Ventures, Threshold Ventures, and Redesign Health.

Founded in 2020, Calibrate has already raised more than $127M, including a $5.1M seed round and a $22.5M Series A.

Metabolic Telehealth 

Combining FDA-approved prescription medication with behavioral therapy, Calibrate offers lifestyle coaching and weight management services.

Taking a holistic approach to weight loss, the company’s year-long metabolic reset program is $129/month while the metabolic assessment alone is $249.

  • 2021 revenues have reached $21M, exceeding projections of $10–12M.
  • Members report an average annual body weight loss of 14%.
  • The company is experiencing 51% month-over-month growth.

Looking ahead, as Calibrate expands its offering, it also plans to target enterprise sales, including employers and insurers.

Weight of the World

A mounting crisis, obesity and diabetes are skyrocketing.

  • 40% of US adults are obese and 100M Americans have diabetes/prediabetes.
  • In the US, the total cost of chronic diseases due to obesity/overweight is $1.72T.

For its part, Calibrate is eyeing the growing opportunity in the $500M weight loss prescriptions segment as part of the broader $270B weight loss market.

From all angles, digital health startups are hoping to alleviate the metabolic health epidemic.

  • In April, Virta Health added $133M in funding at a $2B valuation for its diabetes reversal treatment.
  • In May, digital weight loss app Noom was valued at $3.7B in a $540M funding round.
  • In recent months, glucose monitoring upstarts Levels, Supersapiens, and Ultrahuman have raised millions in funding.

Punchline: Diabetic or not, 88% of Americans are metabolically unhealthy and at increased risk of death and disease. Whether it’s telehealth, behavioral therapy, or prescription medication, expect to see more founders and investors pursue solutions to this problem.